论文部分内容阅读
The title compound(C50H44O10) was synthesized and structurally determined by single-crystal X-ray diffraction method. It crystallizes in monoclinic, space group P21/c with a = 16.713(4), b = 13.189(3), c = 19.434(5) , β = 104.411(4)°, Mr = 804.85, Dc = 1.288 g/cm3, V = 4149.2(17) 3, Z = 4, F(000) = 1696, μ(MoKa) = 0.089 mm-1, T = 296(2) K, 7279 independent reflections with 3172 observed ones(I > 2σ(I)), R = 0.0520 and wR = 0.1203 with GOF = 0.928(R = 0.1464 and wR = 0.1657 for all data). The calixarene moiety maintains the symmetric cone conformation through intramolecular O–H···O hydrogen bonds. Preliminary bioassays indicated that the title compound has a potent inhibitory activity against the strand transfer process of HIV-1 integrase.
It crystallizes in monoclinic, space group P21 / c with a = 16.713 (4), b = 13.189 (3), c = 19.434 ( 5 = .4, β = 104.411 (4) °, Mr = 804.85, Dc = 1.288 g / cm3, V = 4149.2 (17) 3, Z = 4, F R = 0.1464 and wR = 0.1657 for all data, R = 0.1464 and wR = 0.1657 for all data), T = 296 (2) K, 7279 independent reflections with 3172 observed ones (I> 2σ The biomarker indicates the title compound has a potent inhibitory activity against the strand transfer process of HIV-1 integrase.